Cargando…
Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy
INTRODUCTION: Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains uncle...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016096/ https://www.ncbi.nlm.nih.gov/pubmed/33789880 http://dx.doi.org/10.1136/jitc-2020-002262 |
_version_ | 1783673786701185024 |
---|---|
author | Ferdinandus, Justin Metzenmacher, Martin Kessler, Lukas Umutlu, Lale Aigner, Clemens Kambartel, Karl-Otto Grünwald, Viktor Eberhardt, Wilfried Ernst Erich Fendler, Wolfgang Peter Herrmann, Ken Faehling, Martin Christoph, Daniel Christian |
author_facet | Ferdinandus, Justin Metzenmacher, Martin Kessler, Lukas Umutlu, Lale Aigner, Clemens Kambartel, Karl-Otto Grünwald, Viktor Eberhardt, Wilfried Ernst Erich Fendler, Wolfgang Peter Herrmann, Ken Faehling, Martin Christoph, Daniel Christian |
author_sort | Ferdinandus, Justin |
collection | PubMed |
description | INTRODUCTION: Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy. METHODS: This is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. RESULTS: Out of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months. CONCLUSION: After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued. |
format | Online Article Text |
id | pubmed-8016096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-80160962021-04-21 Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy Ferdinandus, Justin Metzenmacher, Martin Kessler, Lukas Umutlu, Lale Aigner, Clemens Kambartel, Karl-Otto Grünwald, Viktor Eberhardt, Wilfried Ernst Erich Fendler, Wolfgang Peter Herrmann, Ken Faehling, Martin Christoph, Daniel Christian J Immunother Cancer Clinical/Translational Cancer Immunotherapy INTRODUCTION: Immunotherapy is the new standard of care in advanced non-small cell lung cancer (NSCLC). Recently published data show that treatment discontinuation after 12 months of nivolumab treatment is associated with shorter survival. Therefore, the ideal duration of immunotherapy remains unclear, and finding markers of beneficial outcomes is of great importance. Here, we determine the proportion of complete metabolic responses (CMR) in patients who have not progressed after 24 months of immunotherapy. METHODS: This is a retrospective analysis of 45 patients with positron emission tomography using 2-[18F]fluoro-2-deoxy-D-glucose imaging for assessment of residual metabolic activity after at least 24 months. CMR was defined as uptake in tumor lesions below background levels, using mediastinum as a reference. RESULTS: Out of 45 patients, 29 patients had a CMR (64%). CMR was observed more frequently in non-first-line patients. Patients with CMR were younger (median 65.7 vs 75.5, p=0.03). Fourteen patients with CMR have discontinued therapy and have not progressed until time of analysis; however, median follow-up was only 5.6 (range 0.8–17.0) months. CONCLUSION: After a minimum of 24 months of palliative immunotherapy for NSCLC, CMR occurred in almost two thirds of patients. Potentially, achievement of CMR might identify patients, for whom palliative immunotherapy may be safely discontinued. BMJ Publishing Group 2021-03-31 /pmc/articles/PMC8016096/ /pubmed/33789880 http://dx.doi.org/10.1136/jitc-2020-002262 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Clinical/Translational Cancer Immunotherapy Ferdinandus, Justin Metzenmacher, Martin Kessler, Lukas Umutlu, Lale Aigner, Clemens Kambartel, Karl-Otto Grünwald, Viktor Eberhardt, Wilfried Ernst Erich Fendler, Wolfgang Peter Herrmann, Ken Faehling, Martin Christoph, Daniel Christian Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title | Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title_full | Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title_fullStr | Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title_full_unstemmed | Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title_short | Complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
title_sort | complete metabolic response in patients with advanced non-small cell lung cancer with prolonged response to immune checkpoint inhibitor therapy |
topic | Clinical/Translational Cancer Immunotherapy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016096/ https://www.ncbi.nlm.nih.gov/pubmed/33789880 http://dx.doi.org/10.1136/jitc-2020-002262 |
work_keys_str_mv | AT ferdinandusjustin completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT metzenmachermartin completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT kesslerlukas completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT umutlulale completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT aignerclemens completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT kambartelkarlotto completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT grunwaldviktor completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT eberhardtwilfriedernsterich completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT fendlerwolfgangpeter completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT herrmannken completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT faehlingmartin completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy AT christophdanielchristian completemetabolicresponseinpatientswithadvancednonsmallcelllungcancerwithprolongedresponsetoimmunecheckpointinhibitortherapy |